Second primary malignancies with lenalidomide therapy for newly diagnosed myeloma: a meta-analysis of individual patient data

Antonio Palumbo, Sara Bringhen, Shaji K Kumar, Giulia Lupparelli, Saad Zafar Usmani, Anders Waage, Alessandra T Larocca, Bronno R Van Der Holt, Pellegrino Musto, Massimo Offidani, Maria Teresa Petrucci, Andrea Evangelista, Sonja Zweegman, Ajay K Nooka, Andrew Spencer, Meletios Athanasios Dimopoulos, Roman Hajek, Michele M Cavo, Paul G Richardson, Sagar LonialGiovannino Ciccone, Mario Boccadoro, Kenneth Carl Anderson, Bart M Barlogie, Pieter Sonneveld, Philip L McCarthy

Research output: Contribution to journalArticleResearchpeer-review

217 Citations (Scopus)


Background: Lenalidomide has been linked to second primary malignancies in myeloma. We aimed to pool and analyse available data to compare the incidence of second primary malignancies in patients with and without lenalidomide exposure. Methods: We identified relevant studies through a search of PubMed and abstracts from the American Society of Clinical Oncology, American Society of Hematology, and the International Myeloma Workshop. Randomised, controlled, phase 3 trials that recruited patients with newly diagnosed multiple myeloma between Jan 1, 2000, and Dec 15, 2012, and in which at least one group received lenalidomide were eligible for inclusion. We obtained individual patient data (age, sex, date of diagnosis, allocated treatment and received treatment, duration of treatment and cause of discontinuation, maintenance treatment, date of first relapse, date of second primary malignancy diagnosis, type of second primary malignancy, date of death or last contact, and cause of death) by direct collaboration with the principal investigators of eligible trials. Primary outcomes of interest were cumulative incidence of all second primary malignancies, solid second primary malignancies, and haematological second primary malignancies, and were analysed by a one-step meta-analysis. Findings: We found nine eligible trials, of which seven had available data for 3254 patients. 3218 of these patients received treatment (2620 had received lenalidomide and 598 had not), and were included in our analyses. Cumulative incidences of all second primary malignancies at 5 years were 6?9 (95 CI 5?3-8?5) in patients who received lenalidomide and 4?8 (2?0-7?6) in those who did not (hazard ratio [HR] 1?55 [95 CI 1?03-2?34]; p=0?037). Cumulative 5-year incidences of solid second primary malignancies were 3?8 (95 CI 2?7-4?9) in patients who received lenalidomide and 3?4 (1?6-5?2) in those that did not (HR 1?1 [95 CI 0?62-2?00]; p=0?72), and of haematological second primary malignancies were 3?1 (95 CI 1?9-4?3) and 1?4 (0?0-3?6), respectively (HR 3?8 [95 CI 1?15-12?62]; p=0?029). Exposure to lenalidomide plus oral melphalan significantly increased haematological second primary malignancy risk versus melphalan alone (HR 4?86 [95 CI 2?79-8?46]; p
Original languageEnglish
Pages (from-to)333 - 342
Number of pages10
JournalThe Lancet Oncology
Issue number3
Publication statusPublished - 2014

Cite this